4 Best Biopharma Stock Trades 2013

Below are some of the best trades in the Biopharma Stock Sector since January 2013. I have gathered my research from a pretty good stock investment forum, 4-Trader.  It's all free.  I would never ask you to pay for anything on my site.  No catches, no gimmicks.

If you want to search for other Sectors or other Countries, you can check them out here:

4-Trader.com Stock Sector Research

4-Trader.com Healthcare Sector:  Biotech and Pharmaceutical 

These are highly potential  breakout stocks that I have researched and just posting their results and how to learn more about these Top Stocks in the Healthcare Sector.  More Specifically Biotech and Pharmaceutical Stocks that I predict will be doing very well in the next year with the stock market doing well and the Obamacare being implemented in 2014.  There were a lot to choose from so I pick the best ones that I thought had potential for further gains.

Make Money Off Obamacare

As bad as Obamacare is for business, I think it will improve the Healthcare Sector in the upcoming year and these are all good stocks that I would recommend.  But you can perform your own due diligence yourself, this are the ones that stuck out to me.

Top 4 Biopharma Trades

These are the all the best trades since January, most are above 50% in stock share growth.  Most have higher potentials for further earnings.  These are my own personal 4 picks that I thought were the best of the bunch.

Santarus Inc. (SNTS)

Chelsea Therapeutics Rockets Upward on Clinical Trial Data

Image via Wikipedia So yesterday I was cautiously optimistic on Chelsea Therapeutics' 2nd go around with their Phase III Clinical Trial and I will eat crow on that story. I am simply a cautious investor. There is nothing wrong with that. I just want the facts before I jump into an investment.

But if the story had gone the other way, people would have lost a lot of money today upon negative results. I just wasn't so sure it would work this time around. I see now that it will be a good run-up candidate pending FDA approval. The stockcould go down a little after all the hoopla today and when it hits a bottoming price I see it as a buy. I'm not so sure I would be buying it just yet as there will be some selloff after today's news but putting a limit price target on the stock could be a good idea.

Most of the trading was done by Wall Street Investors in Pre-Market hours, so if you bought it this morning you might have lost a small chunk of change. Wall St. has a funny way of controling things before and after trading hits the floor for the everyday investor. They like to control the floor and let the little guy suffer sometimes. I won't go too much into that but you have to be careful when playing with the big boys in this game. Today is a good example if you look at todays stock chart.

Google Finance: CHTP

Here is the news today.

Chelsea Therapeutics 2nd Clinical Trial Pending Results

Image via CrunchBase

From Wikinvest: Chelsea Therapeutics (CHTP) traded higher Friday closing at 5.06 +0.94 for a 22% gain. I am showing some caution for Chelsea Therapeutics as this Clinical Trial was previously rejected last September. News from that rejection from Sept. 2009: Chelsea Therapeutics (CHTP) Dives After Trial Did Not Demonstrate Statistically Significant Improvement Versus Placebo. For more information on the 2009 Clinical Trial you can read more about it here: Chelsea Therapeutics Reports Preliminary Phase III Data of Droxidopa for Treatment of Symptomatic Neurogenic Orthostatic Hypotension

The catalyst that pushed Chelsea higher this past Friday was based on an Upgrade of Chelsea pending a 2nd Phase III clinical trial results.